In another setback to Sanofi (SNY), the Philippine government has suspended clearance for is dengue vaccine and fined the company a symbolic $2,000 for allegedly failing to comply with product-registration terms.
The move comes less than two months after the drug maker caused a public health uproar by reporting that Dengvaxia could worsen — rather than prevent — future cases of the mosquito-borne virus in people who had not previously been infected. Approximately 800,000 children in the Philippines were vaccinated as part of a government-sponsored program.
About the Author Reprints
